Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK), ...

Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.

Regular exercise supports immune health by improving the circulation of your immune cells and reducing inflammation, but overtraining may weaken defenses.

A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as NAFLD, represents the most prevalent liver disorder globally, ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein ...